再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

交易中 02-03 15:36:25 EST

16.46

+0.16

+0.95%

最高17.19	最低16.17	成交量58.08万
今开16.75	昨收16.30	日振幅6.26%
总市值18.42亿	流通市值18.00亿	总股本1.12亿
成交额962.63万	换手率0.53%	流通股本1.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":16.455,"timestamp":1770150975315,"preClose":16.3,"halted":0,"volume":580815,"delay":0,"changeRate":0.009509202453987581,"floatShares":109371942,"shares":111962803,"eps":-1.922867,"marketStatus":"交易中","change":0.155,"latestTime":"02-03 15:36:25 EST","open":16.745,"high":17.19,"low":16.17,"amount":9626327.90982,"amplitude":0.062577,"askPrice":16.46,"askSize":100,"bidPrice":16.45,"bidSize":150,"shortable":3,"etf":0,"ttmEps":-1.922867,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770152400000},"marketStatusCode":2,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":16.3,"preHourTrading":{"tag":"盘前","latestPrice":16.59,"preClose":16.3,"latestTime":"08:48 EST","volume":4,"amount":66.36,"timestamp":1770126517893,"change":0.29,"changeRate":0.017791,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":16.3,"preClose":16.3,"latestTime":"16:10 EST","volume":34027,"amount":554640.54,"timestamp":1770066605106,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.725969,"impliedVol":0.6169,"impliedVolPercentile":0.4104},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2608858816","title":"【券商聚焦】浦银国际维持再鼎医药(09688)“买入”评级 料公司有望在2027年迎来净利润端的盈亏平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2608858816","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608858816?lang=zh_cn&edition=full","pubTime":"2026-02-02 14:59","pubTimestamp":1770015599,"startTime":"0","endTime":"0","summary":"基于公司近况以及短中期商业化展望，该机构将2025E/2026E净亏损预测调整为1.9亿美元/2.1亿美元，该机构预计公司有望在2027年迎来净利润端的盈亏平衡。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974391","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"2607089064","title":"海通国际：维持再鼎医药(09688)“优于大市”评级 双引擎助力实现长期全球价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2607089064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607089064?lang=zh_cn&edition=full","pubTime":"2026-01-30 10:58","pubTimestamp":1769741898,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海通国际发布研报称，维持再鼎医药“优于大市”评级，对应目标价为35.25港元，该行调整2025-2027年收入预测至4.7/5.0/7.2亿美元，一方面通过引进并商业化海外产品获取稳定收入，另一方面依托跨境平台推动创新管线全球开发。此外，管理层预计一项新型联合用药方案的I期临床研究预计于2026年上半年启动。公司预计在2026年下半年公布用于健康受试者的首次人体研究数据。管理层预计将于年内完成临床试验申报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"2603937939","title":"2026年JPM大会诺华、阿斯利康、辉瑞等巨头超百亿美元交易频现，中国资产成最大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937939","media":"药厂那点事儿","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603937939?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:05","pubTimestamp":1768518317,"startTime":"0","endTime":"0","summary":"巨头交易频现，中国资产备受青睐。诺华公司周二下午宣布了一项针对中国生物技术公司泽璟生物的许可交易。再生元计划在2026年公布该药用于肥胖治疗的中国3期临床试验结果，并启动全球3期临床开发计划。截至2025年第三季度，19家大型制药公司现金储备总额超过1700亿美元，2025年前三季度产生了约1400亿美元的自由现金流，为大规模并购交易提供了充足的资金支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","06855","06978","ZLAB","01530","01477","02359","02269","BK1191","BK1574","02268","BK1161","AAPG","09688"],"gpt_icon":0},{"id":"2603462820","title":"智通港股早知道 | 财政部召开财政金融协同促内需会议 白宫宣布对特定半导体等加征25%关税","url":"https://stock-news.laohu8.com/highlight/detail?id=2603462820","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603462820?lang=zh_cn&edition=full","pubTime":"2026-01-15 07:40","pubTimestamp":1768434028,"startTime":"0","endTime":"0","summary":"参加会议的包括国务院有关部门和单位、省级财政部门、财政部各地监管局以及相关经办机构。美国白宫宣布对特定半导体等加征25%关税美国白宫14日宣布，从15日起对部分进口半导体、半导体制造设备和衍生品加征25%的进口从价关税。根据该通知书，市监总局已根据中华人民共和国反垄断法开始对本公司进行调查。经本公司财务部门初步测算，预计2025年度实现归属于上市公司股东的扣除","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a7a093e7059d2a399d631855b31ce739","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02269","BK1501","02268","BK1515","BK4585","WXXWY","BK1591","BK1615","BK1610","01875","SMH","BK1147","LU1794554557.SGD","BK1502","09961","LU1720050803.USD","BK1247","BK1516","03759","SOXX","BK1521","BK1584","BK1564","BK1571","TCOM","BK4588","300759","ZLAB","BK1142","BK1589","BK1189","BK1617","09688"],"gpt_icon":1},{"id":"2603690983","title":"药明生物与再鼎医药就创新T细胞衔接子达成研究服务协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2603690983","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603690983?lang=zh_cn&edition=full","pubTime":"2026-01-14 19:24","pubTimestamp":1768389864,"startTime":"0","endTime":"0","summary":"1月14日，药明生物宣布与再鼎医药已针对一款创新T细胞衔接子（TCE）签署研究服务协议，再鼎医药将获得该TCE在实体瘤适应症治疗上的全球独家开发与商业化权利。该TCE的发现是基于药明生物专有的CD3技术平台，并结合多特异性抗体研究能力和前沿生物学洞见。基于该平台开发的三款TCE分子目前均处于临床开发阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143619133231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK4526","BK1610","LU1688375341.USD","LU0708995583.HKD","ZLAB","LU1242518857.USD","LU0327786744.USD","LU0326950275.SGD","BK1141","LU0039217434.USD","LU0516422440.USD","LU0417516902.SGD","LU0588546209.SGD","BK1588","SG9999002463.SGD","LU0516423091.SGD","LU0456827905.SGD","LU0516422952.EUR","BK1576","LU0043850808.USD","LU0979878070.USD","LU0359202008.SGD","LU0417516738.SGD","BK4588","LU0348825331.USD","BK4139","LU0320764599.SGD","IE00B0JY6N72.USD","LU0572944931.SGD","LU0140636845.USD","BK1161","LU0456846285.SGD","BK4585","LU1720050803.USD","LU2039709279.SGD","LU0181495838.USD","BK4531","BK4548","LU1794554557.SGD","LU2488822045.USD","09688","LU0052750758.USD","BK1589","LU0307460666.USD","LU0819121731.USD","LU0516423174.USD","02269","LU0823426480.USD","LU3063872942.SGD"],"gpt_icon":0},{"id":"2603666362","title":"再鼎医药午前涨超7% 公司亮相JPM医疗健康大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2603666362","media":"新浪港股","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603666362?lang=zh_cn&edition=full","pubTime":"2026-01-14 11:27","pubTimestamp":1768361220,"startTime":"0","endTime":"0","summary":"　　再鼎医药午前股价上涨7.16%，现报15.71港元，成交额1.97亿港元。　　据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日进行展示。呫诺美林曲司氯铵胶囊预计于2026年上半年通过聚焦、高效的商业化策略上市，重点包括医生教育、真实世界的证据生成以及为2027年有望纳入国家医保药品目录做好准备。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-14/doc-inhhfvyz4202820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4531","BK1588","159760","LU1280957306.USD","09688","XBI","BK4534","BK4207","LU2746668461.USD","LU2430703178.SGD","LU1668664300.SGD","LU1720051108.HKD","LU2430703251.USD","IE00BJTD4V19.USD","LU0251132253.USD","XLV","LU0820562030.AUD","LABU","LU0417517546.SGD","LU2264538146.SGD","IE0034235188.USD","IE00B3S45H60.SGD","LU1244550221.USD","LU2237443549.SGD","BK4533","LU1551013425.SGD","IE00B1BXHZ80.USD","LU0149725797.USD","LU2106854487.HKD","LU2242649171.HKD","LU0689472784.USD","BK4585","LU0345769631.USD","LU2381873111.SGD","ZLAB","BK1161","LU2357305700.SGD","LU2237443978.SGD","IE00BYXW3230.USD","LU2756315318.SGD","LU1366192091.USD","LU2236285917.USD","IE00BN8TJ469.HKD","LU0006306889.USD","LU1894683348.USD","LU2456880835.USD","IE00BWXC8680.SGD","BK4566","LU0942090050.USD","IE00B1XK9C88.USD"],"gpt_icon":0},{"id":"2603866383","title":"港股异动 | 再鼎医药(09688)涨超7% 公司亮相JPM医疗健康大会 Zoci有望成为肿瘤领域首款全球上市产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2603866383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603866383?lang=zh_cn&edition=full","pubTime":"2026-01-14 11:10","pubTimestamp":1768360208,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超7%，截至发稿，涨7.09%，报15.7港元，成交额1.85亿港元。消息面上，据再鼎医药官微消息，1月13日，公司在第44届摩根大通医疗健康大会上介绍2026年战略重点及临床开发进展，相关内容将于1月14日进行展示。其中，Zocilurtatug pelitecan有望成为再鼎医药肿瘤领域首款全球上市产品，计划在2026年底前启动三项注册性关键研究，包括二线及以上小细胞肺癌、一线小细胞肺癌和神经内分泌癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2462157665.USD","IE00BWXC8680.SGD","LU1032466523.USD","LU2488822045.USD","LU2756315318.SGD","LU0820561909.HKD","XBI","BK1588","LU1720051017.SGD","LU0820561818.USD","LU1064131342.USD","LU0964807845.USD","LU0265550946.USD","LU0256863811.USD","IE00B1BXHZ80.USD","LU1244550221.USD","BK4585","BK4581","LU1496350171.SGD","IE00BKVL7J92.USD","IE00BJTD4N35.SGD","LU0211326839.USD","IE0034235303.USD","LU2381873111.SGD","LU0048584097.USD","LU0882574139.USD","ZLAB","IE00BLSP4452.SGD","LABU","LU0106261372.USD","LU0417517546.SGD","LU2054465674.USD","IE00BZ1G4Q59.USD","LU1261432733.SGD","LU0234572021.USD","LU1548497426.USD","159760","LU0211331839.USD","09688","LU0238689110.USD","LU0320765646.SGD","LU1496350502.SGD","XLV","LU1670627923.USD","LU2505996681.GBP","IE00BHPRN162.USD","BK4548","IE00BN8TJ469.HKD","LU2430703095.HKD","IE0034235188.USD"],"gpt_icon":0},{"id":"2593447132","title":"港股异动 | 再鼎医药(09688)早盘涨超4% 重磅抗精神分裂症新药凯捷乐在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2593447132","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593447132?lang=zh_cn&edition=full","pubTime":"2025-12-24 09:44","pubTimestamp":1766540643,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药早盘涨超4%，截至发稿，涨3.45%，报14.1港元，成交额5919.14万港元。消息面上，12月23日，再鼎医药宣布，中国国家药品监督管理局已批准呫诺美林曲司氯铵胶囊（凯捷乐）的新药上市申请，用于治疗成人精神分裂症。这是70余年来首个获批的具有全新作用机制的精神分裂症疗法，为精神分裂症治疗带来了根本性突破。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 再鼎医药(09688)早盘涨超4% 重磅抗精神分裂症新药凯捷乐在中国获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4139","BK4531","BK1574","BK4526","BK4548","09688","BK1588","BK4588","LU2488822045.USD","BK4585","ZLAB"],"gpt_icon":0},{"id":"2593410921","title":"70 余年来首个！BMS/再鼎医药精神分裂症新药国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2593410921","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593410921?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:53","pubTimestamp":1766494418,"startTime":"0","endTime":"0","summary":"12 月 23 日，再鼎医药宣布，NMPA 已批准呫诺美林曲司氯铵胶囊的新药上市申请，用于治疗成人精神分裂症。新闻稿指出，这是70 余年来首个获批的具有全新作用机制的精神分裂症疗法，为精神分裂症治疗带来了根本性突破。截图来源：Insight 数据库2024 年 9 月，美国 FDA 批准该药用于治疗成人精神分裂症。对比 KarXT 此前的精神分裂症相关研究，该研究中未出现新的或预期外的安全性信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223221618a6c650b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223221618a6c650b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BMS","BK4526","BK4531","BK4548","09688","BK4585","ZLAB","LU2488822045.USD","BK4588"],"gpt_icon":0},{"id":"2590073525","title":"纳斯达克中国金龙指数涨0.86% 热门中概股涨多跌少 禾赛涨3.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590073525","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590073525?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:51","pubTimestamp":1765551073,"startTime":"0","endTime":"0","summary":"金吾财讯 | 纳斯达克中国金龙指数涨0.86%；热门中概股涨多跌少，禾赛涨3.9%，金山云涨3.8%，网易、再鼎医药、亚朵涨近3%；小马智行、百度、日月光半导体、台积电跌近2%，亚玛芬体育跌1.4%，BOSS直聘跌1.3%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/OTc4NDY1YzgwYTY5ZDI5OGQwMTAxMzU2NDM1Mjg5Ng==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OTc4NDY1YzgwYTY5ZDI5OGQwMTAxMzU2NDM1Mjg5Ng==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"295347","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","LU1282649810.SGD","ASX","LU0994945656.USD","BK4526","BK4608","LU2360032135.SGD","03145","LU1989772840.SGD","TTTN","LU0965508806.USD","IE00BHPRN162.USD","LU1152091168.USD","LU2750360641.GBP","KC","LU1037948541.HKD","LU2028103732.USD","LU1623119135.USD","LU1688375341.USD","IE00BZ199S13.USD","02525","IE0004445239.USD","HSAI","BK4607","LU0572939691.SGD","BZ","LU0594300179.USD","BK4605","AS","LU1868837722.USD","LU2054465674.USD","LU2750360997.AUD","LU2237443978.SGD","LU0109392836.USD","LU2460026573.USD","BK4527","LU0965509010.AUD","LU1508157978.USD","LU2663582299.SGD","LU0889565833.HKD","ATAT","LU1989772923.USD","LU0353189680.USD","LU1880383440.USD","LU1267930813.SGD","NTES","ZLAB","LU2294711713.HKD"],"gpt_icon":0},{"id":"1102748254","title":"港股创新药概念股盘初普跌！歌礼制药-B跌近6%、金斯瑞生物科技跌近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102748254","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102748254?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:44","pubTimestamp":1765331074,"startTime":"0","endTime":"0","summary":"12月10日，港股创新药概念股盘初普跌，$歌礼制药-B(01672)$跌近6%，$金斯瑞生物科技(01548)$跌近5%，$再鼎医药(09688)$跌超3%，$康方生物(09926)$、$药明康德(00013)$、$药明生物(02269)$跌超2%.","market":"hk","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"41fbc90a42b871f5da0d5addc6c1afd7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","HK0000320264.USD","LU2039709279.SGD","LU0417516738.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","SG9999002562.SGD","LU0516422366.SGD","IE00B543WZ88.USD","LU0327786744.USD","BK1610","LU0307460666.USD","LU1880383366.USD","LU0417516571.SGD","02269","BK1574","LU0823426308.USD","LU3063872942.SGD","LU1242518857.USD","BK1161","BK1588","01548","LU0561508036.HKD","09688","BK4526","BK4139","LU0634319403.HKD","ZLAB","LU0516423174.USD","LU0348783233.USD","LU0979878070.USD","LU1242518931.SGD","BK1576","LU0819121731.USD","LU0348784397.USD","SG9999002463.SGD","09926","LU0359201612.USD","LU2476274308.USD","LU0039217434.USD","IE00B0JY6N72.USD","BK4531","LU0320764599.SGD","LU2476274720.SGD","LU0052750758.USD","LU0051755006.USD","LU0348735423.USD","BK1515","LU0456827905.SGD","IE00BPRC5H50.USD","BK1583","06978","LU0348767384.USD","LU0359202008.SGD","LU0823426480.USD","BK1589","01672","LU1961090484.USD","01477","LU0856984785.SGD","LU0456846285.SGD","LU0588546209.SGD","LU0140636845.USD","LU0708995583.HKD","LU0043850808.USD","LU2399975544.HKD","BK4585","HK0000320223.HKD","LU0540923850.HKD","LU0572944931.SGD","LU0516422440.USD","BK1141","LU0417516902.SGD","LU0516422952.EUR","LU0181495838.USD","LU1794554557.SGD","LU0326950275.SGD","LU1720050803.USD","LU2488822045.USD","LU1688375341.USD","BK4548","LU2778985437.USD","HK0000306685.HKD","LU0348766576.USD","LU0516423091.SGD","HK0000306701.USD","BK1521","BK4588"],"gpt_icon":0},{"id":"2588082048","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588082048","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588082048?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:36","pubTimestamp":1764761787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年12月1日(美国东部时间)，本公司根据2024年股权激励计划向3名承授人授出可认购合共11,800股美国存托股份的购股权并向6名承授人涉及合共22,665股美国存托股份的受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","09688","LU2488822045.USD","BK4139","BK4526","BK1574","BK1588","BK4585","BK4588","ZLAB","BK4531","BK1161"],"gpt_icon":0},{"id":"2584945044","title":"再鼎医药(09688)根据股权激励计划发行200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584945044","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584945044?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:13","pubTimestamp":1763554404,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年11月19日，该公司发行200万股新股，由受托人持有，以兑现按先前披露的条款(1)归属根据 2017，2022及2024年股权激励计划所授出的股份奖励，及(2)如适用，行使根据2015，2017，2022及2024年股权激励计划所授出的期权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1574","BK4585","BK4531","ZLAB","09688","BK4526","BK1161","LU2488822045.USD","BK4588","BK4139","BK4548"],"gpt_icon":0},{"id":"2584295603","title":"热门中概股悉数下跌 纳斯达克中国金龙指数跌1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584295603","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584295603?lang=zh_cn&edition=full","pubTime":"2025-11-18 23:11","pubTimestamp":1763478667,"startTime":"0","endTime":"0","summary":"金吾财讯 | 热门中概股悉数下跌，纳斯达克中国金龙指数跌1.07%。BOSS直聘(BZ)跌5.51%，拼多多(PDD)跌5.39%，瑞幸咖啡(LKNCY)跌4.38%，亚朵(ATAT)跌4.17%，禾赛(HSAI)跌3.55%，再鼎医药(ZLAB)跌2.87%，腾讯音乐(TME)跌2.75%，蔚来(NIO)跌2.94%，万国数据(GDS)跌2.49%。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZGIxNTcwOGM2NDcyYjg1YTQwZGM4YzE1NmM3NzkzMzkxMDg4NTA3.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZGIxNTcwOGM2NDcyYjg1YTQwZGM4YzE1NmM3NzkzMzkxMDg4NTA3.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"294574","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0871576103.HKD","BK4532","LU0329678170.USD","PDD","SG9999011746.SGD","HK0000320264.USD","LU2039709279.SGD","LU1048588211.SGD","BK4501","LU0594300419.USD","NIO.SI","LU0359202008.SGD","IE0034224299.USD","LU0516422952.EUR","BK4553","LU0456842615.SGD","LU0456846285.SGD","BK4108","LU0235996351.USD","LU1794554557.SGD","HSAI","BZ","BK4563","LU0561508036.HKD","LU0516422366.SGD","LU1868837565.USD","LU1719994722.HKD","LU0633140727.USD","01698","09866","TME","TTTN","LU0307460666.USD","LU0143863784.USD","EVS.SI","LU0823426308.USD","NIO","BK4531","GDS","LU0052750758.USD","BK4503","LU0823038988.USD","ZLAB","LU0683595622.HKD","ATAT","LU2087589342.USD","LU1880383366.USD","LKNCY","LU0516422440.USD","BK4534"],"gpt_icon":0},{"id":"2582351030","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2582351030","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582351030?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:16","pubTimestamp":1762852561,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年11月10日(美国东部时间)，公司根据2024年股权激励计划向1名承授人授出可认购合共500股美国存托股份的购股权并向78名承授人涉及合共7.21万股美国存托股份的受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4548","09688","BK4585","BK4588","BK1161","BK4531","ZLAB","BK4526","BK4139","LU2488822045.USD","BK1574"],"gpt_icon":0},{"id":"2582435357","title":"【券商聚焦】浦银国际维持再鼎医药(ZLAB/09688)“买入”评级 指核心管线Zoci未来12个月催化剂丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2582435357","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582435357?lang=zh_cn&edition=full","pubTime":"2025-11-11 15:29","pubTimestamp":1762846196,"startTime":"0","endTime":"0","summary":"3Q25产品毛利率为59.5%，仍然延续2Q25以来同比环比均下降的趋势。基于此，以及考虑到四季度因医保谈判带来的渠道补偿，该机构预计四季度艾加莫德销售增速或较为温和。重点关注全球管线资产研发进展，其中核心管线Zoci未来12个月催化剂丰富，包括2L+SCLC1期颅内疗效数据更新、1LSCLC联用1期数据、NEC1期数据均有望于1H26读出，且公司预计Zoci+PDL1±chemo注册临床及NEC具备注册潜力的队列有望于2026年开启。此外，公司亦有望于2026年开展更多Zoci与新型疗法的联用1期试验。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1969424","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB","09688"],"gpt_icon":0},{"id":"1190254329","title":"异动解读 | 再鼎医药盘中大跌5.05%，三季度业绩未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1190254329","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190254329?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:38","pubTimestamp":1762526296,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大跌5.05%，引发市场关注。这一跌幅主要与公司近期发布的第三季度财报有关。根据再鼎医药公布的2025年第三季度业绩报告，公司总收入为1.16亿美元，同比增长14%。值得注意的是，再鼎医药将2025年全年总收入指引调整为至少4.6亿美元。这一调整可能被市场解读为公司对未来业绩预期的下调，进一步加剧了投资者的忧虑情绪。在生物科技股整体走弱的背景下，再鼎医药的股价承压下行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"gpt_icon":0},{"id":"2581091628","title":"再鼎医药(09688)第三季度总收入同比增长14%，达1.161亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091628","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581091628?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:17","pubTimestamp":1762438643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药 公布2025年第三季度业绩，总收入同比增长14%，达1.161亿美元;经营亏损为4880万美元，同比收窄28%，调整后的经营亏损收窄42%至2,800万美元;调整2025年全年总收入指引为至少4.60亿美元。其中，产品收入净额为1.154亿美元，2024年同期为1.018亿美元，同比增长 13%，按固定汇率计算同比增长14%。这一增长主要是由纽再乐和鼎优乐销售额增长所驱动，部分被则乐销量放缓所抵销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药(09688)第三季度总收入同比增长14%，达1.161亿美元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ZLAB","BK4548","BK4588","LU2488822045.USD","BK4531","BK1574","BK4526","BK4585","BK4139","BK1161","BK1588","09688"],"gpt_icon":1},{"id":"2581797592","title":"再鼎医药胃癌新药临床研究因疗效不足终止，相关研发进程受影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2581797592","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581797592?lang=zh_cn&edition=full","pubTime":"2025-11-05 09:23","pubTimestamp":1762305780,"startTime":"0","endTime":"0","summary":"11月5日，再鼎医药（09688/ZLAB）发布公告，公司的合作伙伴安进公司于2025年11月4日宣布，关于贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的1b/3期临床研究FORTITUDE-102，由于临时分析显示疗效不足，该研究已被停止。此决定是基于资料监查委员会的要求。公司表示将继续与安进公司密切合作，并在适当时提供进一步的更新。此次研究的停止将影响公司的相关研发进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511053555495121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4526","BK4531","BK1161","LU2488822045.USD","BK4548","ZLAB","BK1588","BK1574","BK4585","BK4139","09688","BK4588"],"gpt_icon":0},{"id":"2581944767","title":"再鼎医药(09688)：关于安进公司贝玛妥珠单抗 1b/3期临床研究FORTITUDE-102的更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2581944767","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581944767?lang=zh_cn&edition=full","pubTime":"2025-11-05 08:04","pubTimestamp":1762301064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司的合作伙伴及该研究申办方安进公司，于2025年11月4日在其2025年第三季度财报发布会期间宣布，评估贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的 1b/3 期临床研究FORTITUDE-102，由于根据资料监查委员会的要求所做的临时分析显示疗效不足已停止。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1057294990.SGD","LU1571399168.USD","LU0289739699.SGD","LU1023059063.AUD","LU1983299246.USD","BK4588","BK1161","BK4566","LU2242646821.SGD","AMGN","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU2242652126.USD","ZLAB","09688","BK4531","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4526","BK4139","BK4585","LU2468319806.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU1061106388.HKD","LU2488822045.USD","BK1574","LU0320765992.SGD","BK4581","LU0868494617.USD","BK4599","BK4548","LU0122379950.USD","LU0058720904.USD","LU0889565916.HKD","IE0002141913.USD","BK1588","BK4534","LU2112291526.USD","BK4533","IE00B2B36J28.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.076},{"period":"1month","weight":-0.0594},{"period":"3month","weight":-0.3704},{"period":"6month","weight":-0.579},{"period":"1year","weight":-0.4005},{"period":"ytd","weight":-0.076}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.085823},{"month":2,"riseRate":0.444444,"avgChangeRate":0.011163},{"month":3,"riseRate":0.25,"avgChangeRate":-0.083122},{"month":4,"riseRate":0.375,"avgChangeRate":0.008126},{"month":5,"riseRate":0.5,"avgChangeRate":0.028309},{"month":6,"riseRate":0.5,"avgChangeRate":0.075433},{"month":7,"riseRate":0.5,"avgChangeRate":0.004927},{"month":8,"riseRate":0.625,"avgChangeRate":0.000651},{"month":9,"riseRate":0.375,"avgChangeRate":-0.055585},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.047464},{"month":11,"riseRate":0.555556,"avgChangeRate":0.101421},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.029495}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}